1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is a devastating neurodegenerative disorder without cure. It is associated with progressive cognitive decline that affects aging population. Without effective and immediate approaches aimed to prevent or modify the disease, by 2050 the number of affected individuals can reach 100 million ([@bb0285]). Extracellular amyloid beta (Aβ) plaques and intracellular neurofibrillary tangles comprised of hyperphosphorylated Tau protein (pTau) represent the major hallmarks of AD ([@bb0005]). The etiology of sporadic AD, which represents over 95% of all cases, is unknown with age being the single risk factor. Familial AD (FAD) is caused by mutations in presenilin 1 and presenilin 2 (PS1 and PS2), and amyloid precursor protein (APP), all of which are involved in the abnormal processing of APP leading to increased levels of Aβ ([@bb0070]). The specific molecular mechanisms of sporadic and familial AD are still under investigation hindering the development of effective therapeutic approaches. There is compelling data to demonstrate that increased levels of Aβ compromise multiple cellular pathways. Thus, the downstream cognitive symptoms can be caused by non-Aβ factors including oxidative stress, inflammation, mitochondrial dysfunction, and lipid perturbations ([@bb0220]). At the same time, emerging data from multiple animal studies and clinical investigations suggest a tight interconnection between Aβ and pTau, and therefore, development of strategies to reduce levels of both could be beneficial ([@bb0100], [@bb0160]).

However, to date, all clinical trials designed to low levels of Aβ by either blocking activity of β or γ secretases, preventing Aβ aggregation, or promoting Aβ clearance by immunotherapy have failed ([@bb0030]) emphasizing an urgent need to find new therapies for AD. One of the emerging therapeutic approaches involves modulation of cellular energetics that includes activation of AMP-activated protein kinase (AMPK), a master regulator of intracellular energy metabolism ([@bb0275]). AMPK activation was shown to promote neuronal survival after the exposure to Aβ peptides, induce autophagy-dependent degradation of Aβ, and reduce tau phosphorylation ([@bb0205], [@bb0270], [@bb0310], [@bb0315]). Resveratrol-induced activation of AMPK reduced cognitive impairment in SAMP8 mouse model of AD ([@bb0235]). AMPK activation is also linked to an increase in life span in model organisms ([@bb0110], [@bb0145], [@bb0265]), and to prevention of obesity and insulin resistance, conditions that significantly and independently increase risk of AD ([@bb0050], [@bb0245]). Metformin, an FDA approved drug to treat type 2 diabetes and potent activator of AMPK ([@bb0215]), reduces tau phosphorylation and improves neuronal insulin signaling and AD-related neuropathological changes in vitro ([@bb0045], [@bb0115]). However, activation of AMPK has been shown to contribute to AD pathology and cause brain damage in AD mice ([@bb0010], [@bb0150]). Similar, metformin was also shown to increase Aβ levels by up-regulating the activity of beta-site APP-cleaving enzyme 1 (BACE1), which could account for increased risk of AD development in diabetic patients treated with metformin ([@bb0095], [@bb0165]). Thus, the development of safe metabolic modulators for AD treatment represents a considerable challenge.

Previously, we have synthesized several tricyclic pyrone compounds based on the structures of pyripyropene A, a potent acyl-CoA:cholesterol O-acyltransferase inhibitor ([@bb0180]), and arisugacin, a potent acetylcholinesterase inhibitor ([@bb0085], [@bb0185]). One of the compounds, CP2, was found to attenuate Aβ-induced toxicity in primary cortical neurons ([@bb0140]) and reduce Aβ aggregation in 5 × transgenic animal model of familial AD ([@bb0075]). Here, we report that mild inhibition of mitochondrial complex I with tricyclic pyrone compound CP2 reduces levels of both Aβ and pTau and averts the development of cognitive and behavior phenotype in three mouse models of FAD. We identified CP2 binding site in the redox center of complex I, and defined the molecular mechanism that involves activation of AMPK and restoration of axonal trafficking. Our results provide compelling evidence that modulation of complex I activity represent promising and alternative therapeutic strategy for AD.

2. Material and Methods {#s0010}
=======================

2.1. Chemicals {#s0015}
--------------

CP2 was synthesized as described by [@bb0090] and purified using HPLC.

2.2. Animals {#s0020}
------------

Animal care and handling procedures were approved by the Mayo Clinical Institutional Animal Care and Use Committee in accordance with the National Institutes of Health\'s *Guide for the Care and Use of Laboratory Animals*. Details utilized animal models, treatment regimens and behavior and memory tests are presented in Supplemental Experimental Procedures.

2.3. Gene Expression {#s0025}
--------------------

Hippocampal tissue from untreated and CP2-treated (4 months) APP/PS1 (n = 5) and NTG (n = 5) mice was examined for the markers of inflammation (iNOS, RANTES and interferon-gamma), cholesterol efflux (ABCA1 and ABCG1) and housekeeping gene (β-actin). Total RNA was extracted with RNeasy kit (Qiagen). Gene expression assay (real time qPCR) was performed with the primers/probe kit (Applied Biosystem Inc.) according to the manufacturer\'s protocol. The expression levels of each gene from each group of animals were calculated as per cent of the expression relative to the control NTG animals after normalization for β-actin. Experiments were repeated twice in two independent cohorts.

2.4. Neuronal Cultures {#s0030}
----------------------

Primary hippocampal and cortical neurons were cultured as described by [@bb0295]. Neurons from neonatal animals (P1) were isolated and plated from individual pups; genotyping was done prior to the day of experiment. All experiments were performed in neurons 7 days in culture unless specifically stated. Details are described in Supplemental Experimental Procedures.

2.5. CP2 Quantification {#s0035}
-----------------------

Animals were euthanized via cervical dislocation. Organs were harvested on ice and immediately flash frozen in liquid nitrogen. On the day of analysis, tissue was homogenized, and CP2 was extracted with a mixture of ethyl acetate and 1-propanol (9:1), and analyzed using LC/MS/MS mass spectrometer. Benzenetetracarboxylic acid (BTA) was used as an internal standard (see Supplemental Experimental Procedures for details).

2.6. Brain Amyloid {#s0040}
------------------

Amyloid plaques were visualized using immunofluorescence labeling and confocal microscopy as previously described ([@bb0135]). Three brain slices were examined from each mouse. Average particle size of the plaques was quantified using Image J 1.45 (rsbweb.nih.gov/ij/) (see Supplemental Experimental Procedures for details).

2.7. Aβ ELISA {#s0045}
-------------

Soluble Aβ levels were determined in brain tissue isolated from CP2-treated APP/PS1 mice 7 months old ([@bb0105]). Details are presented in Supplemental Experimental Procedures.

2.8. Axonal Trafficking {#s0050}
-----------------------

Imaging of mitochondrial trafficking in live cortical neurons and data analysis was done as described by [@bb0290], [@bb0295]. Details are described in Supplemental Experimental Procedures.

2.9. Subcellular Fractionation and CP2 Localization {#s0055}
---------------------------------------------------

Cortical neurons and brain tissue from animals treated with CP2 for 4 months were homogenized, and subcellular fractionation was done using differential centrifugation as described by [@bb0175]. Concentration of CP2 in cellular fractions was determined using LC/MS/MS as described above.

2.10. Mitochondrial Respiration {#s0060}
-------------------------------

Mitochondrial respiration and rate of glycolysis was determined in cortical neurons (E17) isolated from WT mice using an XF24 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, MA, USA) as described by [@bb0325]. Details of experiment are described in Supplemental Experimental Procedures.

2.11. ATP, ADP, and AMP Levels {#s0065}
------------------------------

ATP, ADP and AMP levels in neurons and brain tissue were estimated using HPLC. Details of experiment are described in Supplemental Experimental Procedures.

2.12. Citrate Synthase Assay {#s0070}
----------------------------

The citrate synthase activity was determined in brain tissue of CP2-treated and untreated WT and APP/PS1 mice (n = 5 per each group) according to the manufacturer\'s instructions (Sigma-Aldrich, Co.).

2.13. Activity of Complexes I--V {#s0075}
--------------------------------

Complex I--V enzymatic activity was measured photometrically ([@bb0280]). Details of experiment are described in Supplemental Experimental Procedures.

2.14. NAD^+^/NADH Levels {#s0080}
------------------------

WT cortical neurons were treated with vehicle (0.001% DMSO) or different concentrations of CP2 for 24 h before NAD^+^/NADH levels were determined using Luminescence assay (Promega) according to the manufacturer\'s instructions.

2.15. H~2~O~2~ Treatment {#s0085}
------------------------

WT cortical neurons were pre-treated with different concentrations of CP2 for 24 h, after that 1 mM H~2~O~2~ was added for 2 h. Cell viability was determined using CellTiter-Glo® Luminescent Cell Viability Assay (Promega) according to the manufacturer\'s instructions.

2.16. Transmission Electron Microscopy {#s0090}
--------------------------------------

EM images of hippocampal brain tissue from FAD mice were obtained as described by [@bb0295].

2.17. Western Blotting {#s0095}
----------------------

Western blotting was conducted as described ([@bb0295]); see Supplemental Experimental Procedures for details.

2.18. Theoretical Model of the CP2-Bound FMN Subunit of Human Mitochondrial Complex I {#s0100}
-------------------------------------------------------------------------------------

For details on low-mass molecular dynamics simulations see Supplemental Experimental Procedures.

2.19. Data Analysis {#s0105}
-------------------

Statistical analyses of means for more than two groups were performed using one-way analysis of variance (ANOVA) with the categories of genotype and age as independent factors followed by the Newman--Keuls post-hoc test for multiple comparisons. For analyses of means involving only two groups with a sample size n \< 30, the F-test was used to determine if the variances between the two groups were significantly different. For samples with a significant difference in variance, the Welch\'s *t* test was applied. Two-tailed *t*-test was applied for the samples with an insignificant difference in variance or where n ≥ 30. The null hypothesis was rejected at the 0.05 level. All statistical computations were carried out using Prism (Graphpad Software). Axonal trafficking videos were manually analyzed using LSM Image Browser (version 4.2, Zeiss Microimaging, Thornwood, New York, USA) ([@bb0295]). Unpaired *t*-test with Welch\'s correction was used for analyzing axonal trafficking data. In all cases, α = 0.05 was considered significant. All values are presented as mean ± standard error.

3. Results {#s0110}
==========

3.1. CP2 Averts Cognitive and Behavior Phenotype in FAD Mice {#s0115}
------------------------------------------------------------

We have previously identified small molecule tricyclic pyrone CP2 ([Fig. 1](#f0005){ref-type="fig"}A) that protects cells against Aβ toxicity, and reduces brain Aβ in 5 × FAD mice ([@bb0075], [@bb0140]). To examine the molecular mechanism, we first tested whether CP2 penetrates the blood--brain barrier (BBB). C^14^-Labeled CP2 was injected intraperitoneally to wild type (WT) mice, and levels were measured in the brain tissue 30 min post-injection (Fig. S1A, B). Results suggest that CP2 rapidly accumulates in the brain. Additional pharmacokinetics studies conducted in plasma of WT mice after intravenous or oral administration demonstrated that CP2 bioavailability is 43% (Fig. S1C, D).

To examine the effect of CP2 administration on the development of behavior and memory phenotype in vivo, breeding heterozygous APP and PS1 mice were treated with 25 mg/kg/day CP2 in drinking water and progeny with all four genotypes were produced with the expected ratio ([Fig. 1](#f0005){ref-type="fig"}B). F1 animals continued to receive CP2 through life till 14 months of age. F1 APP and PS1 heterozygous mice also produced multiple litters ([Fig. 1](#f0005){ref-type="fig"}B, F2). CP2-treated P and F1 mice were well groomed, displayed no physical differences compared to non-transgenic (NTG) littermates, with fecundity prolonged up to 14 months of age, while untreated counterparts were heavier and stopped producing progeny earlier in life ([Figs. 1](#f0005){ref-type="fig"}C, D and S2). Histopathological examination of newborn F2 mice treated in utero and F1 mice treated through life ([Fig. 1](#f0005){ref-type="fig"}B) demonstrated lack of developmental or other abnormalities. Average concentration of CP2 in the brain of newborn mice was \~ 90 μM, and in adult mice \~ 130 μM, regardless of the duration of treatment ([Table S1](#ec0010){ref-type="supplementary-material"}). Highest concentrations were found in brain, heart, and reproductive organs, while levels in the liver were the lowest ([Table S2](#ec0015){ref-type="supplementary-material"}).

The effect of chronic CP2 treatment starting in utero on the development of memory and behavior phenotype was determined with a battery of techniques. CP2-treated 56-weeks old APP and PS1 mice performed significantly better on hanging bar and on the rotating rod ([Fig. 1](#f0005){ref-type="fig"}E, F) compared to NTG mice and untreated counterparts. Results of novel object recognition (NOR) test confirmed the development of progressive memory deficit in untreated PS1 and APP mice starting at 30 weeks of age ([Fig. 1](#f0005){ref-type="fig"}G, H). In contrast, CP2-treated FAD mice did not demonstrate cognitive impairment at any age tested ([Fig. 1](#f0005){ref-type="fig"}G, H).

We next investigated whether CP2 administered to adult pre-symptomatic mice delayed the onset of the disease. Double transgenic APP/PS1 mice have accelerated AD phenotype with amyloid deposition and altered behavior in Y-maze present at 3 months of age ([@bb0065]). APP/PS1 mice treated with CP2 starting at 2.5 months of age ([Fig. 2](#f0010){ref-type="fig"}A) outperformed their untreated counterparts in the hanging bar test and maneuvering on accelerating rod evident after 4 months of treatment ([Fig. 2](#f0010){ref-type="fig"}B, C), and did not develop anxiety in the open field test ([Fig. 2](#f0010){ref-type="fig"}D). Similar to APP and PS1 mice, CP2 treatment averted the development of cognitive decline in APP/PS1 animals preserving the ability to discriminate between novel and familiar objects ([Fig. 2](#f0010){ref-type="fig"}E). Memory protection was detected after 2 months of treatment. In the T-maze, CP2-treated APP/PS1 mice displayed higher percentage of spontaneous alternations compared to NTG or untreated APP/PS1 animals, indicating a superior working memory and intact exploratory behavior ([Fig. 2](#f0010){ref-type="fig"}F).

3.2. CP2 Treatment Reduces Soluble and Insoluble Aβ {#s0120}
---------------------------------------------------

Levels of amyloid beta in the brain tissue of CP2-treated and untreated FAD mice were established using confocal microscopy ([@bb0135]). We found that treatment for 4 months starting at presymptomatic age of 2.5 months ([Fig. 2](#f0010){ref-type="fig"}A) resulted in a 50% reduction in plaques compared to age- and sex-matched untreated APP/PS1 mice similar to our previous results in 5 × FAD mice ([@bb0075]) ([Figs. 3](#f0015){ref-type="fig"}A and S3). CP2-treated APP/PS1 mice also had a significant decrease in the levels of soluble Aβ42 detected using ELISA ([Fig. 3](#f0015){ref-type="fig"}B, C). These data suggest that cognitive protection induced by CP2 is accompanied with significant decrease in brain Aβ.

3.3. Modulation of Complex I Activity Augments Mitochondrial Bioenergetics {#s0125}
--------------------------------------------------------------------------

We next assessed CP2 localization in cortical neurons and brain tissue of WT and APP/PS1 mice. Subcellular fractionation and HPLC analysis revealed that CP2 accumulated in enriched mitochondrial fractions isolated from CP2-treated neurons in vitro ([Fig. 3](#f0015){ref-type="fig"}D, E). Similar, CP2 predominantly was detected in enriched mitochondrial fractions isolated from different brain regions of CP2-treated WT and APP/PS1 mice (Fig. S4). Notably, CP2 levels were highest in the mitochondrial fractions from the hippocampus of both WT and APP/PS1 mice compared to other brain regions or nuclear or cytoplasmic fractions. Overall CP2 levels were higher in all fractions in APP/PS1 mice compared to WT animals consistent with its reported ability to bind Aβ ([@bb0075]).

To evaluate whether CP2 affects mitochondrial bioenergetics, we simultaneously measured oxygen consumption rate (OCR) and glycolysis (ECAR, extracellular acidification rate) in intact WT cortical neurons using a Seahorse XF24 extracellular flux analyzer ([Figs. 4](#f0020){ref-type="fig"} and S5A, B). We found that CP2-treated neurons exhibited significantly lower basal OCR relative to the vehicle-treated cells ([Fig. 4](#f0020){ref-type="fig"}A, B). We next investigated whether CP2 affected individual components of electron transport chain (ETC) by adding specific pharmacological inhibitors to CP2-treated and untreated cells and measuring OCR ([Fig. 4](#f0020){ref-type="fig"}A, B). A decrease in OCR after the addition of the Complex V inhibitor oligomycin was compatible in treated and untreated neurons indicating that CP2 did not affect ATP synthase (Fig. S5B). However, we found that CP2 significantly augmented spare respiratory capacity (SRC) evident as an increase in OCR in response to the addition of mitochondria uncoupler FCCP ([Figs. 4](#f0020){ref-type="fig"}A, B and S5B). SRC is an indicator of the mitochondrial ability to produce additional energy under conditions of increased workload or stress, which is essential for long-term cellular survival and function ([@bb0020]). Similarly, CP2 increased mitochondrial state apparent ([Fig. 4](#f0020){ref-type="fig"}D) and respiratory control ratio ([Fig. 4](#f0020){ref-type="fig"}E), and reduced proton leak ([Fig. 4](#f0020){ref-type="fig"}B), which together suggest that ETC in neurons was tightly coupled ([Fig. 4](#f0020){ref-type="fig"}C) providing mitochondria with a considerable bioenergetics reserve and enhanced ability to sustain stress. Indeed, CP2-treated neurons exhibited significantly greater resistance to H~2~O~2~-induced oxidative damage compared to untreated neurons ([Fig. 4](#f0020){ref-type="fig"}F). Reduced respiration could lead to the upregulation of glycolytic pathway. However, the decrease in OCR in response to oligomycin in CP2-treated neurons did not increase ECAR ([Fig. 4](#f0020){ref-type="fig"}G) indicating lack of shift to glycolysis. Thus, CP2 reduces mitochondrial respiration and augments bioenergetics without activating glycolytic pathway.

To further investigate the mechanism of CP2-induced reduction in basal OCR, we substituted specific inhibitors of ETC and FCCP with CP2, one at a time, and evaluated whether CP2 prompts changes in OCR similar to any of the mitochondrial toxicants ([Fig. 4](#f0020){ref-type="fig"}H). Addition of CP2 to intact WT neurons induced changes similar to rotenone/antimycin A but not oligomycin or FCCP suggesting that CP2 inhibits complexes I and/or III ([Fig. 4](#f0020){ref-type="fig"}H). To confirm these findings, we examined the effect of CP2 on the activity of each of the respiratory complexes using enzymatic assays and mitochondria isolated from the brain of WT mice ([Fig. 5](#f0025){ref-type="fig"}A). The addition of CP2 did not alter the activity of complexes II, III, IV and V, while complex I activity was inhibited in a dose-dependent manner. However, the effect was mild compared to 80% of inhibition induced under the same experimental conditions by 10 μM of rotenone (data not shown). It is well known that inhibition of complex I could increase production of reactive oxygen species (ROS) contributing to neurodegenerative processes ([@bb0040]). Nevertheless, the expression of oxidant-inducible gene, heme oxygenase-1 (HO-1) ([@bb0170]), or genes related to inflammation (iNOS, RANTES and interferon-gamma, IFNγ) was not affected in the brain tissue of FAD mice after 4 or 14 months of CP2 treatment ([Figs. 5](#f0025){ref-type="fig"}B, C and S6). Moreover, there appears a trend toward a reduction in expression of HO-I, iNOS, IFNγ in hippocampus of CP2-treated FAD animals. We previously reported that CP2 modestly inhibited the activity of Acyl-CoA:cholesterol acyltransferase, which could increase the expression of cholesterol transporter genes ([@bb0225]). However, gene expression analysis failed to detect activation of cholesterol transporter genes ABCA1 or ABCG1 suggesting that therapeutic effect of CP2 was not related to enhanced cholesterol efflux (Fig. S6). We next assayed the activity of citrate synthase, an enzyme of the mitochondrial matrix that is a marker of organelle integrity and oxidative capacity. Citrate synthase activity in mitochondria isolated from brain tissue of CP2-treated APP/PS1 mice was similar to the observed in WT animals (Fig. S5C) suggesting that CP2 does not damage inner mitochondrial membrane causing leakage of the matrix and does not affect oxidative capacity or TCA cycle. These results are also supported by electron microscopy examination demonstrating robust mitochondrial morphology and cristae organization in the hippocampus of APP, PS1 and APP/PS1 mice treated with CP2 through life ([Fig. 5](#f0025){ref-type="fig"}D).

Furthermore, low-mass molecular dynamics simulations ([@bb0195]) suggest that the cationic CP2 molecule competes with flavin mononucleotide (FMN) for binding to the redox subunit of human mitochondrial complex I ([Fig. 5](#f0025){ref-type="fig"}E, F). FMN is involved in the oxidation of nicotinamide adenine dinucleotide NADH to NAD^+^ ([@bb0055]). Indeed, treatment of WT neurons with CP2 increased levels of NADH in a dose-dependent manner compared to vehicle or an inactive CP2 analog, a neutral tricyclic pyrone compound TP17 ([@bb0075]) ([Fig. 5](#f0025){ref-type="fig"}G). However, inhibition of complex I by CP2 did not lead to a significant drop in the cellular NAD^+^ concentration ([Fig. 5](#f0025){ref-type="fig"}G). These computational and biochemistry studies indicate that competition for binding at the FMN subunit partially reduces complex I activity without inducing oxidative damage or inflammation in vivo.

3.4. Modulation of Complex I Activates AMPK In Vitro and In Vivo {#s0130}
----------------------------------------------------------------

We next measured ATP, AMP and ADP in vitro in primary neurons and in brain tissue of CP2-treated animals ([Fig. 6](#f0030){ref-type="fig"}A--G). Modulation of complex I activity resulted in reduced ATP levels in neurons and dose- and time-dependent increase in AMP/ATP and a decrease in ATP/ADP ratio ([Fig. 6](#f0030){ref-type="fig"}A--D) consistent with previously shown decrease in mitochondrial respiration ([Fig. 4](#f0020){ref-type="fig"}A, B). Similarly, reduced ATP, increased AMP levels and AMP/ATP ratio was detected in the brain tissue of CP2-treated WT and APP/PS1 mice ([Fig. 6](#f0030){ref-type="fig"}E--G). Increase in AMP/ATP is a known activator of AMPK, a major energy sensor in the cell ([@bb0275]). Indeed, CP2 treatment increased levels of pAMPK (Thr172), an activated form of the kinase, in neurons from APP/PS1 mice in time-dependent manner ([Figs. 6](#f0030){ref-type="fig"}H and S7A), and in the brain tissue of WT and APP/PS1 animals in vivo ([Figs. 6](#f0030){ref-type="fig"}I and S7B). AMPK negatively regulates the activity of glycogen synthase kinase 3 beta (GSK3β), which in turn could affect tau phosphorylation ([@bb0080], [@bb0205]). Indeed, CP2-dependent activation of AMPK resulted in concomitant increase in the inhibitory phosphorylation of GSK3β at Ser9 and marked reduction of tau phosphorylation at Ser396/404 in neurons in vitro and in APP/PS1 mice in vivo ([Fig. 6](#f0030){ref-type="fig"}H, I).

3.5. CP2 Restores Axonal Trafficking {#s0135}
------------------------------------

We previously reported that inhibition of axonal trafficking was detected early in embryonic neurons from PS1 and APP/PS1 mice ([@bb0295]). Increased levels of Aβ, pTau and activated GSK3β are implicated in the development of axonal trafficking dysfunction in AD ([@bb0305]). We next explored whether changes induced by modulation of complex I activity positively affected axonal transport. Using established methodology ([@bb0290], [@bb0295]) ([Fig. 7](#f0035){ref-type="fig"}A--C), we evaluated mitochondrial motility in neurons from F2 pups treated with CP2 in utero ([Fig. 1](#f0005){ref-type="fig"}B). Visualization of mitochondrial dynamics in live neurons revealed lack of trafficking inhibition in APP/PS1 and PS1 mice in both anterograde and retrograde directions ([Fig. 7](#f0035){ref-type="fig"}B--D) and significant increase in motile organelles ([Fig. 7](#f0035){ref-type="fig"}E). Since CP2 levels were similar in the brain tissue of neonatal F2 and adult FAD animals ([Table S1](#ec0010){ref-type="supplementary-material"}, P1), we examined whether axonal trafficking was also improved in adult mice in vivo by measuring levels of brain-derived neurotrophic factor (BDNF) in APP/PS1 mice treated with CP2 for 2 months ([Fig. 7](#f0035){ref-type="fig"}F). BDNF provides an essential support for synaptic function, plasticity and neuronal survival. It is delivered to the cell body via retrograde trafficking, and its reduced availability is among the most devastating consequences of axonal trafficking inhibition ([@bb0230]). Restoration of axonal transport and improved BDNF support could positively affect levels of synaptic proteins. Indeed, we found significant increase in synaptophysin and BDNF in brain tissue of CP2-treated APP/PS1 mice ([Fig. 7](#f0035){ref-type="fig"}F--I) consistent with preserved cognitive function.

4. Discussion {#s0140}
=============

We present evidence that modulation of cellular energetics via mild inhibition of mitochondrial complex I reduces levels of both Aβ and pTau and averts the development of cognitive phenotype in multiple FAD mice. Using low-mass molecular dynamics simulations and multiple biochemical approaches, we identified that CP2 competes with FMN for binding to the redox center of human mitochondrial complex I. We conducted comprehensive animal studies utilizing three distinct, transgenic mouse models of FAD with early and late disease onset and two treatment regimens that demonstrate unequivocal protection of mice against cognitive decline as well as enhanced vigor and fecundity relative to untreated groups. We also performed in-depth evaluation of molecular mechanisms in vitro and in vivo determining that changes in cellular energetics led to an increase in AMP/ATP ratio and activation of AMPK, with subsequent reduction in GSK3β and restoration of axonal trafficking ([Fig. 7](#f0035){ref-type="fig"}J). Our findings demonstrate that modulation of mitochondrial function by small-molecule therapeutics could effectively and safely modify or prevent the development of disease validating promising and alternative therapeutic strategy for AD that may offer a practical treatment to patients.

Complex I is the largest and most complicated enzyme of the mammalian OXPHOS system where function of its 45 subunits is not entirely understood. Deficiencies in complex I are associated with various diseases including Parkinson\'s disease, Huntington\'s disease (HD) and AD ([@bb0190]). Complex I is also one of the main contributors to ROS production ([@bb0060]). However, CP2-dependent inhibition of complex I did not induce oxidative damage, inflammation or changes in mitochondrial morphology. Contrary, CP2 augmented mitochondrial bioenergetics increasing SRC and ETC coupling efficiency, conferring neurons with greater ability to resist stress. Chronic treatment for 14 months provided robust preservation of cognitive and motor functions in FAD animals compared not only to untreated counterparts but also to WT mice. The beneficial metabolic adaptation observed in our study may be related to the specific site of CP2 binding to complex I that is encoded by the NADH-ubiquinone oxidoreductase 1 alpha subcomplex subunit 1 (NDUFA1). It is interesting to note that partial deficiency induced by neuron-specific conditional ablation of another subunit of complex I, NDUFA5, also did not increase oxidative damage or inflammation, but contrary to our data, caused mild chronic encephalopathy in mice ([@bb0210]). Moreover, different from rotenone that binds at or close to the ubiquinone binding site(s) of complex I leading to substantial ROS generation ([@bb0035]), binding at the FMN subunit can actually reduce levels of ROS by inhibiting the reaction of semiquinone species with O~2~ that occurs at the flavin center ([@bb0120]). It is also important to note that the extent of complex I inhibition by CP2 was mild. Thus, it did not significantly affect the pool of NAD^+^. At the same time, it is feasible that moderate shift of the equilibrium toward NADH detected in our studies could have an additional benefit compensating for a decline in its neuronal levels associated with age and AD ([@bb0200]). Moreover, since inhibition of complex IV is predominantly linked to Aβ pathology ([@bb0015]), reducing workload through ETC by mild inhibition of complex I could also provide some relief for complex IV. While the detailed correlation between the extent of deficiencies in various ETC complexes and efficacy of CP2 treatment remains to be determined, our pilot data demonstrate that CP2 treatment is efficient in slowing down the development of AD when administered for 6 months to symptomatic APP/PS1 mice starting at 9 months of age (data not shown).

Another important finding of our study is that mild inhibition of complex I resulted in restoration of axonal trafficking. Remarkably, reduction in GSK3β activity, Aβ and pTau was sufficient to restore mitochondrial motility even under conditions where ATP production was slightly reduced. Increased levels of BDNF and synaptic proteins support the notion that trafficking restoration contributes to cognitive protection observed in APP/PS1 mice. These data demonstrates therapeutic value of trafficking restoration in respect to cognitive protection. We previously demonstrated that CP2 binds Aβ preventing its aggregation ([@bb0140], [@bb0255]). However, it remains to be determined to what extent that contributes to therapeutic efficacy observed in the study. While we detected a reduction in Aβ levels, future investigations are needed to establish whether CP2 affects APP processing, Aβ production and/or enhances autophagic clearance via AMPK-dependent inhibition of the mammalian target of rapamycin.

Our data support a counterintuitive therapeutic approach that is based on the inhibition of OXPHOS. However, emerging data demonstrate that the presence of mtDNA mutations encoding subunits of complex I or inhibition of OXPHOS with pharmacological inhibitors is beneficial in preventing obesity and type II diabetes ([@bb0240], [@bb0250], [@bb0300], [@bb0320]), and promoting longevity in model organisms and in humans ([@bb0025], [@bb0125], [@bb0130], [@bb0260]). Activation of AMPK also underlies molecular mechanisms of metabolic reprogramming induced by calorie restriction ([@bb0155]). While we did not detect significant changes in levels of Sirtuin 1 or peroxisome proliferator-activated receptor gamma coactivator 1 alpha after prolonged treatment with CP2 (data not shown), animals maintained healthy body weight, displayed robust performance in motor tests, and were conceiving longer compared to untreated mice. It will be important to further investigate the molecular mechanisms associated with cognitive protection observed in our study and to determine whether metabolic reprogramming induced by this complex I inhibitor could promote an increase in health and life span.

The following are the supplementary data related to this article.Supplementary Materials.Table S1Related to [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}. CP2 concentration in the brain tissue of neonatal mice born from the CP2-treated parents and of adult mice treated with 25 mg/kg/daily over various periods of time.Table S2Related to [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}. Levels of CP2 in various organs in wild-type mice treated with 25 mg/kg/daily via drinking water.Table S3Related to [Fig. 5](#f0025){ref-type="fig"}. Cluster analysis of multiple low-mass molecular dynamics simulations of CP2-bound FMN subunit of human mitochondrial complex I at 300 K and 1 atm.
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![Chronic CP2 treatment averts the development of behavior and memory phenotype in FAD mice.\
(A) CP2 structure. (B) P and F1 animals treated with 25 mg/kg/day CP2 produced F1 progeny that were treated with CP2 till 14 months of age. F2 pups were used for axonal trafficking experiments. (C, D) CP2-treated PS1 (C, light gray; n = 5) and APP (D, light gray, n = 5) mice maintained body weight similar to NTG untreated mice (black, n = 10), while untreated PS1 (C, dark gray, n = 10) and APP (D, dark gray, n = 10) mice accumulated weight with age. \**P* \< 0.05. (E) CP2-treated APP mice (red, n = 5) did not display muscle weakness or altered prehensile reflex in hanging bar test compared to untreated APP animals (gray, n = 10). Black --- untreated NTG, n = 10. \**P* \< 0.05. (F) Time on a rod rotating at 20 rpm. CP2-treated PS1 (orange, n = 5) and APP (dark blue, n = 5); untreated APP (light blue, n = 10), PS1 (gray, n = 10), and NTG mice (black, n = 10). Mice were 56 weeks old. \**P* \< 0.05. (G, H) NOR test demonstrates that CP2-treated APP (G, light orange bars: training session; red bars: NOR, n = 5) and PS1 (H, light blue bars: training session; dark blue bars: NOR, n = 5) mice maintained the ability to recognize a familiar object similar to NTG animals (n = 10) while their untreated counterparts (n = 10 for APP and n = 10 for PS1) lost that ability with age. \**P* \< 0.05. See also Figs. S1 and S2.](gr1){#f0005}

![CP2 treatment of pre-symptomatic APP/PS1 mice prevents the development of AD.\
(A) Treatment regimen in pre-symptomatic APP/PS1 (A/P) mice. (B, C) CP2 protects against the development of motor phenotype evident by the unaltered performance on a hanging bar (B) and accelerating rod (C) after 4 months of treatment. Squares --- WT; triangles --- WT + CP2; diamonds --- A/P; circles --- A/P + CP2. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; n = 8--9 mice per group. (D) A/P mice (circles) treated for 4 months demonstrated normal activity in the cage similar to untreated (squares) and CP2-treated (triangles) WT mice compared to the untreated A/P animals (diamonds). \**P* \< 0.05; \*\**P* \< 0.01 A/P compared to WT; ^\#\#^*P* \< 0.01 A/P + CP2 compared to A/P; n = 8--9 mice per group. (E) NOR test. \**P* \< 0.05; \*\**P* \< 0.01; n = 5--10 mice per group. (F) After 4 months of treatment, A/P mice performed similar to WT animals during spontaneous T-maze exploration while untreated A/P mice displayed prominent memory deficit. \**P* \< 0.05. Data are presented as mean ± SEM.](gr2){#f0010}

![CP2 reduces amyloid levels and accumulates in mitochondria.\
(A) Amyloid plaques in the brain of APP/PS1 mice (blue, n = 5) treated for 4 months are significantly reduced compared to untreated animals (red, n = 5). \**P* \< 0.05. (B, C) Soluble Aβ42 (C) but not Aβ40 (B) is reduced in APP/PS1 mice treated for 6 months (blue, n = 9) compared to untreated animals (red, n = 9). \**P* \< 0.05. (D) CP2 accumulates in mitochondria (HM) fractions isolated from WT neurons treated with 2 μM CP2 for 24 h. CN --- crude nuclear; CYTO --- cytoplasmic fractions. (E) Purity of HM fractions confirmed using EM (scale bar, 1 μm) and Western blotting. Tom 20 --- mitochondrial marker; NP --- nucleoporin. See also Figs. S3 and S4.](gr3){#f0015}

![CP2 augments mitochondrial bioenergetics in neurons.\
(A--E) Bioenergetics parameters estimated in WT cortical neurons treated with 2 μM CP2 (24 h, gray) compared to vehicle-treated neurons (black). Data are mean ± SEM; n = 12--14 replicates per data point, three independent experiments. OCR --- oxygen consumption rate; SRC --- spare respiratory capacity; non-mito --- non-mitochondrial respiration; AA --- antimycin A. Coupling efficiency is presented in (C). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 (Student\'s *t*-test). (F) CP2 protects WT neurons against H~2~O~2~ toxicity. \*\**P* \< 0.01; \*\*\**P* \< 0.001 (Student\'s *t* test). (G) CP2 treatment does not induce glycolysis. Temporal bioenergetic profiling in neurons generated as in (A) after addition of: A --- oligomycin, B --- FCCP, and C --- rotenone (n = 12--14 replicates per data point, three independent experiments). (H) CP2 mimics the effect of rotenone/AA; n = 7. See also Fig. S5.](gr4){#f0020}

![CP2 binds to the flavin mononucleotide subunit of complex I and inhibits its activity without inducing oxidative stress.\
(A) Activity of respiratory complexes I--V in isolated mitochondria treated with different concentrations of CP2. \**P* \< 0.001, two-tailed *t*-test; n = 3--5 replicates per data point. (B, C) CP2 treatment in APP (25 mg/kg/day, 14 months, n = 4) and APP/PS1 (25 mg/kg/day, 4 months, n = 5) mice did not change the expression of HO-1 (B) and iNOS (C) genes compared to untreated NTG (n = 4) or WT mice (n = 5). (D) Electron micrographs of mitochondria in the hippocampus of APP mouse treated with CP2 for 14 months (bottom) compared to untreated APP mouse (top) of the same age. Scale bar, 500 nm (top) and 200 nm (bottom). (E) Overview of the CP2-bound flavin mononucleotide subunit of human complex I. (F) Residues of the complex I subunit that interact with CP2 (the subunit is in stick model; CP2 is in ball-and-stick model; dashed lines denote hydrogen bonds). (G) Levels of NADH and NAD^+^ in WT neurons treated with different concentration of CP2, vehicle or inactive CP2 analog, TP17; n = 8--11 replicates per data point. \*\*\**P* \< 0.00001. See also Fig. S6.](gr5){#f0025}

![CP2 treatment increases AMP/ATP ratio and activates AMPK in vitro and in vivo.\
(A, B) Dose-dependent increase in AMP/ATP (A) and a decrease in ATP/ADP (B) in WT neurons 24 h after CP2 treatment. \**P* \< 0.05; \*\*\**P* \< 0.001; n = 6. (C, D) Time-dependent AMP/ATP increase (C) and ATP/ADP decrease (D) in WT cortical neurons after CP2 treatment. \**P* \< 0.05; \*\*\**P* \< 0.001; n = 6; VEH --- vehicle-treated neurons. Data represent mean ± SEM. (E--G) CP2 (25 mg/kg/day, 2 months) reduces ATP levels in the brain of WT (n = 16) and APP/PS1 (A/P, n = 11) mice (E), and increases levels of AMP (F) and AMP/ATP ratio (G). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (H) CP2 affects levels of pAMPK, pGSK3β (S9), and pTau (S396) in a time-dependent manner in cortical neurons (P1) from APP/PS1 mice. Each lane represents neurons from individual APP/PS1 animal. (I) CP2 (25 mg/kg/day, 2 months) activates AMPK, reduces activity of GSK3β, and decreases levels of pTau (S396) in the brain of APP/PS1 mice. See also Fig. S7.](gr6){#f0030}

![CP2 restores axonal trafficking and increases levels of synaptic markers and BDNF.\
(A) Visualization of mitochondria in live neuron using TMRM and LSM 510 confocal microscope, 100 × oil DIC lens (1.4 NA). Scale bar, 10 mm. (B, C) Representative kymographs showing reduced axonal transport with primarily stationary mitochondria (horizontal lines) in APP/PS1 neurons (B) and significantly greater mitochondrial motility (diagonal lines) in neurons from APP/PS1 mice treated with CP2 in utero (C). Neurons were plated from P1 animals and imaged after 7 DIC. Data analysis for these experiments is presented in D and E. (D) CP2 restores mitochondrial trafficking in anterograde and retrograde directions in neurons from APP/PS1 (A/P, n = 5) and PS1 (n = 5) P1 pups born from the CP2-treated F2 mice. (E) Mitochondria in neurons from newborn mice treaded with CP2 in utero moved more frequently. All values are presented as mean ± standard error. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. (F) Western blotting in brain extracts from APP/PS1 (n = 3) mice treated with CP2 (25 mg/kg/day, 2 months) shows an increase in synaptophysin, BDNF and pAMPK compared to untreated APP/PS1 animals (n = 3). (G--I) Fold differences in protein levels from (F) normalized to tubulin using densitometry. \**P* \< 0.05. (J) Data interpretation.](gr7){#f0035}
